What is the recommended workup for hematuria in a post‑menopausal woman?

Hematuria Workup in Post-Menopausal Women

All post-menopausal women with hematuria require thorough history, physical examination, urinalysis with microscopy, and risk stratification to determine the appropriate imaging and cystoscopy pathway, with the primary goal of excluding urinary tract malignancy.

Initial Evaluation

Before any imaging, every patient must undergo 1:

• Thorough history focusing on:

  • Smoking history (pack-years)
  • Occupational chemical exposures
  • Analgesic abuse
  • History of pelvic irradiation
  • Chronic UTIs
  • Irritative voiding symptoms
  • Prior urologic disease or procedures
  • Anticoagulation use (does NOT alter evaluation requirements)

• Physical examination including:

  • Pelvic examination to assess for atrophic vaginitis, prolapse, or other gynecologic sources
  • Assessment for signs of renal parenchymal disease

• Laboratory testing:

  • Properly collected, non-contaminated urinalysis with microscopy
  • Urine culture if infection suspected (before antibiotics)
  • Serologic testing for renal function

Risk Stratification and Imaging Algorithm

Gross Hematuria

This is a medical urgency requiring full urologic workup regardless of other factors 1. Gross hematuria carries a 30-40% malignancy risk.

• Imaging: CT urography (CTU) is the preferred modality 1
  • Includes unenhanced images, nephrographic phase, and excretory phase (≥5 minutes post-contrast)
  • Thin-slice acquisition with multiplanar reconstruction
• Cystoscopy: Mandatory 1

Microhematuria (≥3 RBCs/HPF on properly collected specimen)

Post-menopausal status itself is a risk factor. Additional risk stratification based on 2, 3:

High-Risk Features:

• Age >60 years (though women >70 have 2.2% bladder cancer incidence 3)
• Smoking history (≥10 pack-years)
• Occupational chemical exposure
• History of pelvic irradiation
• Chronic indwelling foreign body
• History of urologic disease
• Irritative voiding symptoms

Workup for High-Risk Microhematuria:

• CT urography 1
• Cystoscopy 1

Workup for Lower-Risk Microhematuria (fewer risk factors):

• Renal ultrasound may be considered as initial imaging 2
• Cystoscopy based on shared decision-making 2

Important Caveats and Pitfalls

Do NOT Skip Evaluation For:

• Anticoagulation therapy - This does NOT alter the need for full evaluation 1
• Suspected benign causes - Even if interstitial cystitis, atrophic vaginitis, or prolapse is suspected, complete evaluation should proceed unless a clear benign cause is confirmed 1

When to Defer Complete Workup:

Only defer imaging if there is a clearly identified benign cause 1:

• Active menstruation (but post-menopausal women don't menstruate)
• Vigorous exercise within 48 hours
• Confirmed UTI (must confirm with culture; repeat UA after treatment)
• Recent urologic procedure or trauma

Critical: If UTI is suspected, obtain urine culture BEFORE antibiotics, treat infection, then repeat UA. If hematuria persists, proceed with full evaluation 1.

Special Considerations for Post-Menopausal Women:

• Atrophic vaginitis is common but should be confirmed on pelvic exam 1
• Interstitial cystitis should be considered in women with chronic pelvic pain plus microhematuria 1
• Even with these diagnoses, if hematuria persists and risk factors exist, imaging and cystoscopy should not be deferred

Renal Parenchymal Disease

If proteinuria, dysmorphic RBCs, RBC casts, or elevated creatinine suggest glomerular disease:

• Concurrent nephrology evaluation is appropriate
• However, this does NOT preclude urologic evaluation 1
• Both evaluations should proceed in parallel

Follow-Up After Negative Evaluation

If complete risk-appropriate evaluation is negative 2:

• Most patients can be discharged from urology
• Shared decision-making regarding future UA monitoring
• Repeat evaluation IS indicated if:
  • New gross hematuria develops
  • Worsening degree of microhematuria
  • New urologic symptoms emerge
  • Additional risk factors develop

Evidence Quality Note

The 2025 AUA guidelines 2 and 2020 ACR Appropriateness Criteria 1 provide the framework for this approach. Recent validation studies confirm this risk stratification effectively predicts urothelial malignancies (1.5% overall incidence, 3.8% in high-risk patients) 3. The overall malignancy rate in post-menopausal women with microhematuria is approximately 1.4% 4, but this increases substantially with risk factors, justifying aggressive evaluation in appropriate patients.